Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence
Some 30–50% of the global population and almost 20% of the European population actually suffer from chronic pain, which presents a tremendous burden to society when this pain turns into a disability and hospitalization. Palmitoylethanolamide (PEA) has been demonstrated to improve pain in preclinical...
Main Authors: | Damiana Scuteri, Francesca Guida, Serena Boccella, Enza Palazzo, Sabatino Maione, Juan Francisco Rodríguez-Landa, Lucia Martínez-Mota, Paolo Tonin, Giacinto Bagetta, Maria Tiziana Corasaniti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/8/1672 |
Similar Items
-
A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review
by: Giustino Varrassi, et al.
Published: (2024-12-01) -
Effect of palmitoylethanolamide on inflammatory and neuropathic pain in rats
by: Tai-Kyung Seol, et al.
Published: (2017-10-01) -
A randomised controlled trial assessing the potential of palmitoylethanolamide (PEA) to act as an adjuvant to resistance training in healthy adults: a study protocol
by: Zoya Huschtscha, et al.
Published: (2023-03-01) -
Glia, mastociti e affini: nuove prospettive terapeutiche? - Glia, mast cells and related: new therapeutic perspectives?
by: Guido Orlandini
Published: (2011-07-01) -
Glia, mast cells and related: new therapeutic perspectives?
by: Guido Orlandini
Published: (2011-09-01)